| Title | Author(s) | Year | View Count |
 | 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B | Liaw, Y; Gane, E; Leung, N; Zeuzem, S; Wang, Y; Lai, CL; Heathcote, EJ; Manns, M; Bzowej, N; Niu, J; Han, S; Hwang, SG; Cakaloglu, Y; Tong, MJ; Papatheodoridis, G; Chen, Y; Brown, NA; Albanis, E; Galil, K; Naoumov, NV | 2009 | 1,825 |
| The authors reply | Lai, CL; Gane, E; Brown, NA | 2008 | 46 |
| Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial | Chan, HLY; Heathcote, EJ; Marcellin, P; Lai, CL; Cho, M; Moon, YM; Chao, YC; Myers, RP; Minuk, GY; Jeffers, L; Sievert, W; Bzowej, N; Harb, G; Kaiser, R; Qiao, XJ; Brown, NA; Crawford, D; Lim, SG; Chutaputti, A; Poynard, T | 2007 | 138 |
 | 76 week follow up of HBeAg-positive chronic hepatitis B patients treated with telbivudine, adefovir or switched from adefovir to telbivudine | Marcellin, P; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, J; Myers, R; Harb, G; Brown, NA | 2007 | 117 |
| In hepatitis B patients treated with either adefovir or telbivudine, maximal early hbv suppression at 24 weeks predicts optimal one-year efficacy | Marcellin, P; Chan, HLY; Lai, CL; Clio, M; Heathcote, I; Moon, YM; Chao, YC; Myers, R; Harb, G; Brown, NA | 2007 | 101 |
 | Telbivudine versus lamivudine in patients with chronic hepatitis B | Lai, CL; Gane, E; Liaw, YF; Hsu, CW; Thongsawat, S; Wang, Y; Chen, Y; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, NV; Di Bisceglie, AM; Zeuzem, S; Moon, YM; Goodman, Z; Chao, G; Constance, BF; Brown, NA | 2007 | 245 |
| Efficacy of telbivudine vs lamivudine at 2 years in patients with hbeag-positive chronic hepatitis B who are eligible for treatment based on guidelines | Rasenack, J; Poynard, T; Lai, CL; Gane, E; Brown, NA; Heathcote, J | 2007 | 144 |
| Adefovir salvage therapy for virologic breakthrough in telbivudine-treated patients from the globe study | Pane, E; Lai, CL; Min, A; Heathcote, I; Poynard, T; Kurdas, OO; Grange, JD; Brown, NA | 2007 | 102 |
| Telbivudine vs Lamivudine in HBeAg-Positive Patients with CHB: Two-Year Efficacy and Predictors of Response | Lai, CL; Gane, E; Hsu, CW; Chen, YC; Thongsawat, S; Wang, Y; Chen, Y; Naoumov, N; Han, SH; Hwang, SG; Lim, SG; Brown, NA | 2007 | 108 |
| Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications | Zhou, XJ; Lim, SG; Lloyd, DM; Chao, GC; Brown, NA; Lai, CL | 2006 | 237 |
| Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine | Lai, CL; Gane, E; Hsu, CW; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Rasenack, J; Bzowej, N; Naoumov, N; Zeuzem, S; Di Bisceglie, A; Chao, GC; Barbara, A; Constance, F; Brown, NA; Study Group The GLOBE., | 2006 | 188 |
| Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients | DiBisceglie A, A; Lai, CL; Gane, E; Chen, YC; Thongsawat, S; Wang, YM; Chen, YG; Heathcote, EJ; Zeuzem, S; Rasenack, J; Bzowej, N; Han, SH; Naoumov, N; Hwang, SG; Lim, SG; Chao, GC; Fielman, BA; Brown, NA; Study Group The GLOBE, | 2006 | 158 |
| A Randomized Trial of Telbivudine (LdT) vs Adefovir for HBeAg-positive Chronic Hepatitis B: Final Week 52 results | Bzowej, N; Chan, HLY; Lai, CL; Cho, M; Moon, YM; Chao, YC; Heathcote, EJ; Myers, R; Minuk, G; Marcellin, P; Jeffers, L; Sievert, W; Kaiser, R; Harb, G; Chao, GC; Brown, NA | 2006 | 157 |
| A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B | Lai, CL; Leung, N; Teo, EK; Tong, M; Wong, F; Hann, HW; Han, S; Poynard, T; Myers, M; Chao, G; Lloyd, D; Brown, NA | 2005 | 1,110 |
| Final Results of a Phase I/II Dose Escalation Trial of Valtorcitabine in Patients with Chronic Hepatitis B | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lloyd, D; Pietropalolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 131 |
| Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B. | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lyoyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 114 |
| A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection | Lai, CL; Lim, SG; Brown, NA; Zhou, XJ; Lloyd, DM; Lee, YM; Yuen, MF; Chao, GC; Myers, MW | 2004 | 116 |
| Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial. | Lai, CL; Brown, NA; Yuen, RMF; Wai, CT; Lloyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Lim, SG | 2004 | 173 |
| Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B | Perrillo, RP; Lai, CL; Liaw, YF; Dienstag, JL; Schiff, ER; Schalm, SW; Heathcote, EJenny; Brown, NA; Atkins, M; Woessner, M; Gardner, SD | 2002 | 103 |
| Safe and potent suppression of hepatitis B virus (HBV) with L-deoxythymidine (LDT): Results of a dose-escalation trial | Lai, CL; Myers, MW; Pow, DM; Brown, NA; Lee, YM; Yuen, RMF; Lim, SG | 2001 | 115 |
|
